OBJECTIVE: To add to the limited data on the clinical pharmacology of antidepressants during pregnancy, we examined the dose-corrected chiral and racemic levels (level/dose) of fluoxetine (FLX) and norfluoxetine (NorFLX) during pregnancy and early postpartum. METHODS: The authors evaluated 17 pregnant women who received fluoxetine therapy. Doses were recorded weekly across gestation and postpartum. At 20, 30, and 36 weeks of gestation, during delivery, and 12 weeks after delivery, the depression level was assessed with the Hamilton Rating Scale for Depression (HRS-D), and plasma samples were analyzed for levels of S- and R-FLX and S- and R-NorFLX. RESULTS: The mean ratios of the chiral parent drug (S-FLX + R-FLX) to metabolite levels (S-NorFLX + R-NorFLX) decreased across pregnancy. The differences were significant between 20-36 weeks and 30-36 weeks. After delivery, the mean dose-corrected level of the active moiety S-FLX and the mean ratio of the chiral parent drug (S-FLX + R-FLX) to metabolite level (S-NorFLX + R-NorFLX) significantly increased between delivery and 12 weeks postpartum. Most of the fluoxetine-treated subjects experienced remitted depressive episodes and euthymic mood levels during pregnancy and postpartum. CONCLUSIONS: The findings extend earlier reports of increased antidepressant metabolism during pregnancy and refractory metabolism after delivery. These data may inform treatment decisions related to dosing in patients who receive fluoxetine during pregnancy.
OBJECTIVE: To add to the limited data on the clinical pharmacology of antidepressants during pregnancy, we examined the dose-corrected chiral and racemic levels (level/dose) of fluoxetine (FLX) and norfluoxetine (NorFLX) during pregnancy and early postpartum. r> METHODS: The authors evaluated 17 pregnant women who received fluoxetine therapy. Doses were recorded weekly across gestation and postpartum. At 20, 30, and 36 weeks of gestation, during delivery, and 12 weeks after delivery, the depression level was assessed with the Hamilton Rating Scale forDepression (HRS-D), and plasma samples were analyzed for levels of S- and R-FLX and S- and R-NorFLX. r> RESULTS: The mean ratios of the chiral parent drug (S-FLX + R-FLX) to metabolite levels (S-NorFLX + R-NorFLX) decreased across pregnancy. The differences were significant between 20-36 weeks and 30-36 weeks. After delivery, the mean dose-corrected level of the active moiety S-FLX and the mean ratio of the chiral parent drug (S-FLX + R-FLX) to metabolite level (S-NorFLX + R-NorFLX) significantly increased between delivery and 12 weeks postpartum. Most of the fluoxetine-treated subjects experienced remitted depressive episodes and euthymic mood levels during pregnancy and postpartum. r> CONCLUSIONS: The findings extend earlierreports of increased antidepressant metabolism during pregnancy and refractory metabolism after delivery. These data may inform treatment decisions related to dosing in patients who receive fluoxetine during pregnancy.
Authors: B J Ring; J A Eckstein; J S Gillespie; S N Binkley; M VandenBranden; S A Wrighton Journal: J Pharmacol Exp Ther Date: 2001-06 Impact factor: 4.030
Authors: C B Eap; G Bondolfi; D Zullino; L Savary-Cosendai; K Powell-Golay; M Kosel; P Baumann Journal: J Clin Psychopharmacol Date: 2001-06 Impact factor: 3.153
Authors: F F Tessa Ververs; Heronimus A M Voorbij; Petra Zwarts; Svetlana V Belitser; Toine C G Egberts; Gerard H A Visser; Alfred F A M Schobben Journal: Clin Pharmacokinet Date: 2009 Impact factor: 6.447
Authors: Giselle G Hamad; Joseph C Helsel; James M Perel; Gina M Kozak; Mary C McShea; Carolyn Hughes; Andrea L Confer; Dorothy K Sit; Carol A McCloskey; Katherine L Wisner Journal: Am J Psychiatry Date: 2012-03 Impact factor: 18.112
Authors: Sonja A Swanson; Sonia Hernandez-Diaz; Kristin Palmsten; Helen Mogun; Mark Olfson; Krista F Huybrechts Journal: Pharmacoepidemiol Drug Saf Date: 2015-06-04 Impact factor: 2.890
Authors: Dorothy Sit; James M Perel; Stephen R Wisniewski; Joseph C Helsel; James F Luther; Katherine L Wisner Journal: J Clin Psychiatry Date: 2011-07 Impact factor: 4.384
Authors: Georgios Schoretsanitis; Olav Spigset; Julia C Stingl; Kristina M Deligiannidis; Michael Paulzen; Andreas A Westin Journal: Expert Opin Drug Metab Toxicol Date: 2020-04-10 Impact factor: 4.481